Rosuvastatin reduces experimental left ventricular infarct size after ischemia-reperfusion injury but not total coronary occlusion
Open Access
- 1 April 2005
- journal article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 288 (4) , H1802-H1809
- https://doi.org/10.1152/ajpheart.00962.2004
Abstract
This study compared the effects of rosuvastatin on left ventricular infarct size in mice after permanent coronary occlusion vs. 60 min of ischemia followed by 24 h of reperfusion. Statins can inhibit neutrophil adhesion, increase nitric oxide synthase (NOS) expression, and mobilize progenitor stem cells after ischemic injury. Mice received blinded and randomized administration of rosuvastatin (20 mg·kg−1·day−1) or saline from 2 days before surgery until death. After 60 min of ischemia with reperfusion, infarct size was reduced by 18% ( P = 0.03) in mice randomized to receive rosuvastatin ( n = 18) vs. saline ( n = 22) but was similar after permanent occlusion in rosuvastatin ( n = 17) and saline ( n = 20) groups ( P = not significant). Myocardial infarct size after permanent left anterior descending coronary artery occlusion ( n = 6) tended to be greater in NOS3-deficient mice than in the wild-type saline group (33 ± 4 vs. 23 ± 2%, P = 0.08). Infarct size in NOS3-deficient mice was not modified by treatment with rosuvastatin (34 ± 5%, n = 6, P = not significant vs. NOS3-deficient saline group). After 60 min of ischemia-reperfusion, neutrophil infiltration was similar in rosuvastatin and saline groups as was the percentage of CD34+, Sca-1+, and c-Kit+ cells. Left ventricular NOS3 mRNA and protein levels were unchanged by rosuvastatin. Rosuvastatin reduces infarct size after 60 min of ischemia-reperfusion but not after permanent coronary occlusion, suggesting a potential anti-inflammatory effect. Although we were unable to demonstrate that the myocardial protection was due to an effect on neutrophil infiltration, stem cell mobilization, or induction of NOS3, these data suggest that rosuvastatin may be particularly beneficial in myocardial protection after ischemia-reperfusion injury.Keywords
This publication has 31 references indexed in Scilit:
- New concepts in reactive oxygen species and cardiovascular reperfusion physiologyPublished by Oxford University Press (OUP) ,2004
- Diverse Origin and Function of Cells With Endothelial Phenotype Obtained From Adult Human BloodCirculation Research, 2003
- Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitorJournal of the American College of Cardiology, 2002
- Improvement of Left Ventricular Remodeling and Function by Hydroxymethylglutaryl Coenzyme A Reductase Inhibition With Cerivastatin in Rats With Heart Failure After Myocardial InfarctionCirculation, 2001
- HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathwayJournal of Clinical Investigation, 2001
- CD34−Blood‐Derived Human Endothelial Cell ProgenitorsThe International Journal of Cell Cloning, 2001
- Neutrophils are primary source of O2radicals during reperfusion after prolonged myocardial ischemiaAmerican Journal of Physiology-Heart and Circulatory Physiology, 2001
- Cardiomyocyte Death Induced by Myocardial Ischemia and ReperfusionCirculation, 2000
- Myocardial ischemia-reperfusion injury is exacerbated in absence of endothelial cell nitric oxide synthaseAmerican Journal of Physiology-Heart and Circulatory Physiology, 1999
- Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthaseProceedings of the National Academy of Sciences, 1998